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Introduction
We present the preliminary results of our clinical trial test-
ing 2 vaccine strategies in patients with indolent B cell
non-Hodgkin lymphoma (NHL; NCT01239875, clinical-
trials.gov). The primary objective is to determine the safety
and feasibility of the vaccine approaches and secondary
objectives are to describe clinical responses and identify
corresponding immune changes.
Methods
Autologous mature dendritic cells (mDC) were manufac-
tured from leukapheresed cells of NHL patients. For
patients with tumor lymph nodes deemed amenable to
cryoablation by interventional radiologist (arm A), they
received cryoablation of a node and injection of mDC into
the cryoablated node followed by another 1 to 7 intratu-
moral mDC injections. Remaining patients had a tumor
excised to generate tumor lysate ex vivo. mDC were
pulsed with tumor lysate during DC maturation (arm B;
DC-TL). The DC-TL vaccines were injected intradermally
for 4 to 8 doses. Patients are monitored for one year after
vaccines for adverse events and systemic tumor response.
Correlative studies include cellular immune phenotype of
peripheral blood and T cell intracellular cytokine produc-
tions. Planned accrual is 10 patients per arm (total = 20).
Results
To date, 10 patients have accrued to arm A and 5 patients
to arm B. All patients tolerated vaccine treatments without
major adverse events. Of the 10 evaluable patients, there
Mayo Clinic, Rochester, MN, USA
Table 1 Patient responses
Arm ID Age/
Gender
Histology Stage FLIPI/IPI # of prior Tx DC doses Best response Time to next treatment or event (months)
A LSA1 57M Follicular IVA 2 1 2 SD 25
A LSA2 56F Follicular IIIB 4 2 2 SD 14
A LSA3 69M Follicular IVA 3 4 2 PR 22
A LSA4 60F Follicular IVA 3 3 2 PR 20
A LSA5 64F Follicular IVA 5 8 8 PR Not reached (12 mo at the time of abstract.)
A LSA6 81M Follicular IVA 4 1 8 SD Not reached (9 mo at the time of abstract.)
B LSB1 60M Follicular IIIA 3 1 4 SD 6.5
B LSB2 62F Marginal zone IVAE 4 6 4 SD 7.6
B LSB3 65F Follicular IVA 3 2 8 CR Not reached (13 mo at the time of abstract.)
B LSB4 31F Follicular IIIA 2 0 8 PR Not reached (12 mo at the time of abstract.)
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were 1 CR (arm B: 1 / 4; total: 1/10) and 4 PR (arm A: 3/6;
arm B: 1 / 4; total: 5/10) for an ORR of 50% for both arms
(Table 1). Responses have been durable for at least 1 year.
Correlative studies suggest that immune changes can be
used as prognostic biomarkers to predict response. Upon
stimulation, responders’ T cells had increased IFN-g and
or IL-17a and lower IL-4 production than non-responder
T cells. Preliminary analysis of >80 immune phenotypes
using flow cytometry and hierarchical clustering suggest
that, after vaccination, many components within the
immune system of responders change in a different man-
ner from the non-responders.
Conclusions
Both cryoablation and intratumoral mDC vaccination are
feasible and safe in NHL. Treatment responses may cor-
relate with immune system changes. Biosystems analysis
method can be used to develop novel assays as predictive
biomarkers of treatment response.
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